Business
BioSpectrum Asia
India signs MoU with Pfizer to strengthen healthcare innovation ecosystem
In a significant step towards strengthening India's healthcare innovation ecosystem, the Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce and Industry, Government of India, has signed a Memorandum of Understanding (MoU) with US-based Pfizer Limited.
1 min |
BioSpectrum Asia Oct 2025
BioSpectrum Asia
New Zealand to lead new gene therapy trial for muscular dystrophy
The first clinical trial of a new treatment for a rare form of muscular dystrophy is being led by New Zealand-based University of Auckland's Centre for Brain Research.
1 min |
BioSpectrum Asia Oct 2025
BioSpectrum Asia
Scientists in Australia grow living skin in world-first
Australia's University of Queensland (UQ) researchers have been the first in the world to successfully grow fully functioning human skin in a laboratory.
1 min |
BioSpectrum Asia Oct 2025
BioSpectrum Asia
India joins Health AI Global Regulatory Network to strengthen oversight of AI in healthcare
HealthAI - The Global Agency for Responsible AI in Health, has welcomed India as a pioneer country joining the HealthAI Global Regulatory Network (GRN), a global network of health regulators dedicated to the safe and effective use of artificial intelligence (AI) in healthcare.
1 min |
BioSpectrum Asia Oct 2025
BioSpectrum Asia
TVM Capital Healthcare announces first closing of $150 M Southeast Asia Fund
Singapore-based TVM Capital Healthcare, a global private equity investor and operator specialised in healthcare growth capital across emerging markets, has announced the first closing of its $150 million TVM Healthcare Southeast Asia Fund (SEA Fund).
1 min |
BioSpectrum Asia Oct 2025
BioSpectrum Asia
National Yang Ming Chiao Tung University, TSH Biopharm collaborate to foster pharma talent in Taiwan
Taiwan's National Yang Ming Chiao Tung University (NYCU) and TSH Biopharm have signed a five-year industry-academia collaboration Memorandum of Understanding (MOU).
1 min |
BioSpectrum Asia Oct 2025
BioSpectrum Asia
Fujifilm Biosciences introduces BalanCD HEK293 Perfusion A Medium
Fujifilm Biosciences, a global leader in the innovation and manufacture of cell culture solutions for the life science market, has announced the commercial launch of BalanCD HEK293 Perfusion A.
1 min |
BioSpectrum Asia Oct 2025
BioSpectrum Asia
Korea makes smart patch that can run tests using sweat instead of blood
A research team at Korea Advanced Institute of Science and Technology has developed a smart patch that can precisely observe internal changes through sweat when simply attached to the body.
1 min |
BioSpectrum Asia Oct 2025
BioSpectrum Asia
ADB approves $106.9 M to strengthen secondary healthcare services in Sri Lanka
The Asian Development Bank (ADB) has approved a $106.9 million financing package to strengthen Sri Lanka's secondary curative care services, improve communicable disease prevention and control, and enhance the healthcare sector's governance and management capacity.
1 min |
BioSpectrum Asia Oct 2025
BioSpectrum Asia
Epigenic Therapeutics raises $60 M to accelerate clinical development of medicines
China-based startup Epigenic Therapeutics, a clinical-stage innovative drug development company, has announced the completion of a $60 million Series B round of financing led by Lapam Capital, with continued participation from existing investors Qiming Venture Partners and OrbiMed, and addition of new investors including IFSC and a renowned investment firm in the industry.
1 min |
BioSpectrum Asia Oct 2025
BioSpectrum Asia
Avasa secures funding to proceed with US FDA clearance
Auckland-based medtech startup Avasa has secured the first close of its Pre-Series-A capital raise.
1 min |
BioSpectrum Asia Oct 2025
BioSpectrum Asia
WHO publishes report to help countries ensure equitable access to controlled medicines
The World Health Organization (WHO) has published the full edition of its guideline on balanced national controlled medicines policies, marking the first comprehensive global framework designed to ensure access to controlled drugs for medical and scientific uses, while minimising risks to public health that may arise due to misuse and diversion.
1 min |
BioSpectrum Asia Oct 2025
BioSpectrum Asia
Nanyang Biologics partners with NVIDIA, HPE & Equinix to build AI-powered drug discovery platform
Nanyang Biologics (NYB) enters a strategic collaboration with NVIDIA, Hewlett Packard Enterprise (HPE), and Equinix to build 'VECURA'-an artificial intelligence (AI)-powered drug discovery platform that combines advanced predictive models with a proprietary library of millions of natural compounds.
1 min |
BioSpectrum Asia Oct 2025
BioSpectrum Asia
New Mpox vaccine study to launch in outbreak-affected DRC
New research due to launch in the Democratic Republic of the Congo (DRC) will provide important real-world data on the performance of the LC16m8 mpox vaccine in African populations, amid a major outbreak of the deadly virus which remains a continental public health emergency.
1 min |
BioSpectrum Asia Oct 2025
BioSpectrum Asia
Australia to implement new pneumococcal vaccine on National Immunisation Programme
Australian children will now have stronger protection against pneumococcal with the Australian Government implementing a new and improved vaccine on the National Immunisation Programme (NIP).
1 min |
BioSpectrum Asia Oct 2025
BioSpectrum Asia
CUREator backs Monash biotech to advance new therapeutics for polycystic kidney disease
xCystence Bio, a Monash University biotech startup, has secured a top-up funding boost from Brandon BioCatalyst's CUREator incubator to drive the development of urgently needed therapeutics for Polycystic Kidney Disease (PKD).
1 min |
BioSpectrum Asia Oct 2025
BioSpectrum Asia
HKMU licenses tech for non-invasive prostate cancer screening
Hong Kong Metropolitan University (HKMU) recently achieved its first-ever technology licensing agreement, a milestone in the University's efforts to translate research into impactful, real-world applications.
1 min |
BioSpectrum Asia Oct 2025
BioSpectrum Asia
PAHO intensifies call to strengthen vaccination in light of rising measles cases
The Pan American Health Organization (PAHO) is urging countries in the Americas to strengthen vaccination efforts, improve surveillance, and accelerate outbreak response following a rise in measles cases in the region.
1 min |
BioSpectrum Asia Oct 2025
BioSpectrum Asia
Trump's Counter Productive Tariff Moves
On September 25, 2025, US President Donald Trump announced that the United States would impose a 100 per cent tariff on all branded and patented pharmaceutical imports starting October 1, unless the companies importing them are actively building manufacturing facilities in the US, defined as “breaking ground” or “under construction.” As of September 26, no official guidance or regulations had been released regarding how this policy would be implemented. The announcement has raised significant concerns from healthcare stakeholders, particularly the American Hospital Association (AHA), which represents nearly 5,000 hospitals, health systems, networks, and 43,000 individual members.
2 min |
BioSpectrum Asia Oct 2025
BioSpectrum Asia
US FDA grants accelerated approval to first treatment for Barth Syndrome
The US Food and Drug Administration (FDA) has granted accelerated approval to Forzinity (elamipretide) injection as the first treatment for Barth syndrome, in patients weighing at least 30 kg.
1 min |
BioSpectrum Asia Oct 2025
BioSpectrum Asia
"Sebia India will introduce pipeline of new products across Autoimmunity, Infectious Diseases"
France headquartered Sebia, a global leader in specialty diagnostics, is continuing its geographic footprint to better serve its customers. Over the decades, the company has earned worldwide recognition for its pioneering expertise in Multiple Myeloma screening, diagnosis, and monitoring, as well as its leadership in hemoglobinopathies diagnosis. In recent years, Sebia has significantly expanded its portfolio in autoimmunity and infectious disease diagnostics through strategic acquisitions – ORGENTEC in 2021 and ZEUS Scientific in 2022. The company is now all set to strengthen its presence in India, thereby expanding its reach, building talent, and raising awareness. Sebia established its presence in India in 2019, and has achieved consistent double-digit growth year after year. To find out more about the company's growth plans in India, BioSpectrum spoke to Heejin Roh, Vice President – Commercial Operations, Asia Pacific, Sebia. Edited excerpts:
4 min |
BioSpectrum Asia Oct 2025
BioSpectrum Asia
UK offers free chickenpox vaccination for first time to children
Thousands of children will be protected against chickenpox for the first time in England through a new vaccination programme that will keep kids in school and parents in work while also saving the National Health Service (NHS) vital funds.
1 min |
BioSpectrum Asia Oct 2025
BioSpectrum Asia
WHO urges cost effective solutions on NCDs and mental health
The World Health Organization (WHO) has released a new report titled \"Saving lives, spending less\", revealing that an additional investment of just $3 per person annually in tackling noncommunicable diseases (NCDs) could yield economic benefits of up to $1 trillion by 2030.
1 min |
BioSpectrum Asia Oct 2025
BioSpectrum Asia
India Introduces Stricter Cosmeceutical Rules to Tackle Counterfeit Products
A huge craze among consumers for cosmeceuticals, by going into marketing and brand appeal, is setting a dangerous precedent. Above all, fake cosmetic products have flooded the Indian market, which are easily available online and across street markets. Keeping this in mind and to stop unscrupulous ads, the Ministry of Health and Family Welfare, Government of India has officially published the Cosmetics (Amendment) Rules, 2025, on July 29, which introduce a series of changes to the existing Cosmetics Rules, 2020. Experts weigh in on how this Act can be a gamechanger in the cosmeceutical sector, provided strict norms are followed.
6 min |
BioSpectrum Asia Oct 2025
BioSpectrum Asia
Shimadzu launches Gas Chromatograph FluxEdge GC System
Japan-based Shimadzu has released the FluxEdge GC System, equipped with FluxEdge, its proprietary trace gas sampling/switching technology.
1 min |
BioSpectrum Asia Oct 2025
BioSpectrum Asia
AIU and Acumen join hands to transform India-Japan higher education collaboration
The Association of Indian Universities (AIU) and Acumen, part of the Sannam S4 Group, have announced the formalisation of a pivotal strategic partnership through a Memorandum of Understanding (MOU) designed to significantly accelerate the internationalisation of Indian higher education sector, to provide new international study options for Indian students and to create meaningful graduate career outcomes in Japan.
1 min |
BioSpectrum Asia Oct 2025
BioSpectrum Asia
PHC Holdings inks MoU to transfer Eversense CGM distribution to Senseonics
Japan-based PHC Holdings Corporation and its subsidiary Ascensia Diabetes Care, a global diabetes care company, have announced that Ascensia has signed a Memorandum of Understanding (MoU) to transfer the commercial operations for Eversense Continuous Glucose Monitoring (CGM) systems to Eversense maker Senseonics Holdings, Inc.
1 min |
BioSpectrum Asia Oct 2025
BioSpectrum Asia
CSL partners with VarmX on first-in-class coagulation treatment in $2.2 B deal
Australia's CSL Limited has entered into an agreement with privately held Dutch biotech company, VarmX BV, to develop a new treatment to restore blood coagulation in patients taking a FXa inhibitor.
1 min |
BioSpectrum Asia Oct 2025
BioSpectrum Asia
University of Sydney partners with Siemens Healthineers for MRI research capability
Australia's University of Sydney has unveiled a $9 million partnership with Siemens Healthineers centred on the opening of the state's most advanced magnetic resonance imaging (MRI) scanner.
1 min |
BioSpectrum Asia Oct 2025
BioSpectrum Asia
Malaysia and Singapore sign MoU to fast-track medical device market access
The Medical Device Authority (MDA) of Malaysia and the Health Sciences Authority (HSA) of Singapore have signed a Memorandum of Understanding (MOU) to deepen regulatory cooperation and officially launched a 6-month pilot of the Medical Device Regulatory Reliance Programme as part of the MoU.
1 min |